Comparative Pharmacology
Head-to-head clinical analysis: KENALOG versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG versus ORTIKOS.
KENALOG vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid